Technegas
Commercial- Indications
- Pulmonary imaging
Company intelligence / Profile preview
Cyclomedica
Kingsgrove, New South Wales, Australiadnb.com ↗
- Ownership
- Public · CYC
- Development stage
- Commercial
01
Overview
Cyclomedica, through its flagship product Technegas®, is a global leader in nuclear medicine and molecular imaging for respiratory diseases. Technegas® is approved and commercially available in over 65 countries, including recent US FDA approval in 2023. The technology is established as a gold standard for ventilation imaging in the diagnosis of pulmonary embolism and is being expanded into broader indications such as COPD, asthma, long COVID, and other chronic lung diseases. Clinical results have demonstrated high diagnostic accuracy and safety across millions of patient procedures worldwide.
- Therapeutic areas
- OncologyPulmonologyCardiovascular
- Modalities
- DeviceRadiopharmaceuticalNanoparticle
- Industry
- Medical Imaging
02
Drug pipeline
1 asset03
Partnerships
Jubilant Radiopharma/Jubilant Pharma Limited (distribution partnership for RUBY-FILL® cardiac PET agent in EEA)
04
Financials
- Market cap
- $161.3M
- Total revenue
- $0
- Enterprise value
- $111.3M
Beyond the preview
Go deeper on Cyclomedica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyclomedica.